XML 71 R55.htm IDEA: XBRL DOCUMENT v3.22.4

Research & Development ("R&D") Funding Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development funding expense	$ 177,106	$ 200,084	$ 26,289
Upfront payment and premium paid		193,200
Merck to Fund
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development funding expense	50,000
Cytokinetics
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development funding expense	100,000
Theravance Biopharma
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development funding expense	$ 25,000
Funding Agreements With Sanofi
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development funding expense		6,900	20,500
MorphoSys
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development funding expense		90,000
MorphoSys | BioCryst Pharmaceuticals, Inc.
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development funding expense		$ 103,200
Funding Agreement With BioCryst
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development funding expense			$ 5,800

X

- Definition

Research and Development Expense, Upfront Payment and Premium Paid

+ References

No definition available.

+ Details

Name:	rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid
Namespace Prefix:	rprx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=rprx_MerckToFundMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=rprx_CytokineticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=rprx_TheravanceBiopharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=rprx_FundingAgreementsWithSanofiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=rprx_MorphoSysMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=rprx_BioCrystPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=rprx_FundingAgreementWithBioCrystMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: